Navigation Links
IsoTis Reports Interim Results of Vote for Integra Merger
Date:10/16/2007

heir shares. It will also allow their Swiss and Dutch banks and brokers to be more effective informing these stockholders about the transaction, and to take and pass on their votes to the US custodian banks. Approximately 999,000 additional shares voting in favor of the proposed transaction are necessary to approve the Integra acquisition.

IsoTis also announced that it will host two conference calls on October 17, where investors can ask questions about the special stockholders meeting in German, French, Dutch or English:

Conference call details

Date: October 17, 2007

German / French / English operator

Time: 16:30-17:30 CET

Dial In: 00-41-(0)91-610-5609

Dutch / English operator

Time: 17:30-18:30 CET

Dial In: 00-800-4546-4748

The IsoTis Board of Directors continues to believe unanimously that the interests of IsoTis' stockholders are best served by the acquisition by Integra, and that there are no feasible alternatives for the company and the stockholders. If IsoTis is unable to obtain the vote necessary to approve the proposed transaction, the company believes it will have to seek bankruptcy protection.

About IsoTis

IsoTis is an orthobiologics company that develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. IsoTis' current orthobiologics products are bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. IsoTis' current commercial business is highlighted by its Accell line of products, which the company believes represents the next generation in bone graft substitution.

On August 7, 2007 Integra and IsoTis announced that they have reached a definitive agreement to create a global orthobiologics leader. The combination would create a comprehensive orthobiologics portfolio, one of the
'/>"/>

SOURCE IsoTis Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)...  AACC, a global scientific and medical professional ... is pleased to announce that the impact factor ... increased to 7.9 in the 2014 Thomson Reuters ... Chemistry in the top 3% of all ... the research it publishes on laboratory medicine and ...
(Date:6/29/2015)... 2015 According to a new market ... Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), by ... - Global Forecast to 2020", published by MarketsandMarkets, the global ... from $107.56 Million in 2015, at a CAGR of 17.89%. ... 67 F igures spread through 125 ...
(Date:6/29/2015)... 2015   For the seventh year running, Across Health ... overall digital maturity called the Multichannel Maturometer . ... not maturing fast enough. While it,s true that technology ... overall and customers are increasingly "digital natives", pharma still ... engagement.  ...
(Date:6/26/2015)... CITY, Kan. , June 26, 2015 ... PETX ), a pet therapeutics company ... of innovative biopharmaceutical products for companion animals, ... field effectiveness study of capromorelin (AT-002), the ... dogs.  Capromorelin is a small molecule that ...
Breaking Biology Technology:AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... , Data Reported at the 2010 ASCO ... Both Time to Tumor Progression and Overall Survival in ... Arm , QUÉBEC CITY, Jan. 25 /PRNewswire-FirstCall/ ... AEZ) (the "Company"), a late-stage drug development company specialized ...
... thin films for semiconductors in electronic devices, layers of atoms ... materials grow smooth crystals, others tend to develop bumps and ... In the online edition of the journal Science ... how atoms arrange themselves into thin films. Led by assistant ...
... As ... bright spot in terms of employment growth. But that was offset by a rough ride for ... pharmaceutical companies going into 2010 are any indication, the trouble isn,t over just yet. , ... (Vocus) January 21, 2010 -- As one of ...
Cached Biology Technology:Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 2Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 3Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 4Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 5Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 6Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 7Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 8Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 9Watching crystals grow provides clues to making smoother, defect-free thin films 2The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 2The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 3The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 4
(Date:6/16/2015)... GOTHENBURG, Sweden , June 16, 2015 ... 2015 from previously communicated that it will amount to at ... 390 MSEK. Due to the rapid increase in market growth ... from the previously communicated guidance that revenue for 2015 will ... 2015 will amount to approximately 2,200 MSEK. Due ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
(Date:6/9/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ) has ... & Touchless Sensing Market by Technology (Touch-based & ... (Biometric & Sanitary Equipment) & by Geography - ... offering. The total gesture recognition and ... 23.55 Billion by 2020 at a high CAGR ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... bugs grow in intensive care units to develop a ... MRSA and other superbugs in the environment, scientists heard ... General Microbiologys 162nd meeting being held this week at ... a standard sampling regime to take swabs from sinks, ...
... deadliest diseases, caused by the Ebola virus, may finally ... have successfully tested several Ebola vaccines in primates and ... Dr Anthony Sanchez, from the Centers for Disease ... overview of Ebola vaccine development today (Monday 31 March ...
... Multi-Modal Biometric Identification Solution ... and Interoperability, SCHAUMBURG, Ill., March 28 ... it has been selected by the West Virginia,State ... (BIS). Motorola,s latest BIS solution features new algorithms ...
Cached Biology News:MRSA in hospital intensive care -- what's growing where? 2Vaccine for Ebola virus 2Motorola Biometric Identification System Selected by West Virginia State Police 2
...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... skirted micro test tubes are used to ... these tubes have uniform walls for uniform ... separate O-ring screw caps. The O-rings are ... an operating range from -55 to 150 ...
Biology Products: